Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: bunn who wrote (453)	8/27/2006 8:35:36 PM
From: tuck	Read Replies (1) \| Respond to of 510

Bio-Rad has a well received BSE test, though not much beyond that, true. They just sound more interested. I grant you Quest is one of the heavies of diagnostics. Others, well, Roche, but they're crooks in that division. Bayer. Whatever happened to the BioSite collaboration? It just seemed to quietly die. I'm just concerned about not having an update, as last CIPH said, they were going to luanch by year end. One quarter to go and not a peep. Though again, I haven't listened to the latest CCs. Have you? CIPH can't afford another pushout on this. Would mean something's wrong to me. And there's the cash/dilution issue rearing its ugly head if they don't start getting a royalty stream incoming. Cheers, Tuck

To: bunn who wrote (453)	9/7/2006 7:45:04 PM
From: tuck	Respond to of 510

Oh, Bayer and Abbott also have big diagnostics operations, though I hear Abbott's hasn't performed so well of late. Yeah, I'll be curious to hear what Fung has to say next week. My understanding was that Quest controlled the news flow, though. I'm not sure whether it will be positive, negative (i.e. another pushout) or indifferent. I go with the latter, as CIPH would have said something already if important news was imminent. Can't sit on big news for two weeks; it would leak. Cheers, Tuck